MedPage Today -- ORLANDO, May 31 -- A test widely used to monitor ovarian cancer patients for recurrence did not improve survival despite allowing patients to begin second- and third-line therapy earlier, a large European study showed.
MedPage Today -- ORLANDO, May 31 -- A test widely used to monitor ovarian cancer patients for recurrence did not improve survival despite allowing patients to begin second- and third-line therapy earlier, a large European study showed.
